GradedWe grade the evidence
The longevity field, scored on a fixed rubric.
Longevity Graded reads the primary research and grades every longevity and anti-aging telehealth provider on price transparency, clinical oversight, and evidence. We may earn a commission from some links — hype still gets a failing grade.
Top of the scorecard · Grade A
CoreAge Rx
Doctor-reviewed longevity peptides and NAD+ with one published per-protocol price and built-in human support.
Advertising disclosure. We may earn a commission if you start through this link, at no extra cost to you. Affiliate partners are listed first on the scorecard — judge them on the marks. See our disclosure.
Graded evidence
What the evidence actually earns
- Graded review
Longevity Medicine: What's Proven vs Hyped
An honest, evidence-graded tour of the longevity toolkit — what has human outcome RCTs versus what is animal or mechanistic-only.
Read - Graded review
Do NAD+ and Peptides Actually Extend Lifespan?
NAD+ precursors reliably raise NAD+ but show modest, mixed human outcomes. Peptides and growth hormone carry real cautions. An honest evidence review.
Read - Graded review
Rapamycin & Metformin for Longevity: The Evidence
Strong animal data, a glaring human RCT gap. What the PEARL pilot, the TAME rationale, and metformin's observational signal really show.
Read - Graded review
Are Longevity Clinics Worth It?
DTC and IV longevity clinics sit on the weakest evidence in the field. What a critical review found, and how to vet a provider before paying.
Read - Graded review
Rapamycin for Longevity: Hype vs Evidence
Rapamycin is the most reproducible lifespan extender in mice — but there is no human longevity trial. An honest split of the hype from the evidence.
Read - Graded review
What the PEARL Trial Actually Showed About Rapamycin
PEARL was the largest decentralized RCT of rapamycin in healthy aging — and it missed its primary endpoint. An honest readout of what it did and didn't prove.
Read
Well-supported
Backed by controlled trials or hard clinical outcomes — earns our top grades.
Mixed or emerging
Promising signals but incomplete evidence; graded honestly, caveats and all.
Thin or contested
Marketing outrunning the data. We say so plainly — and grade it accordingly.
Read the full rubric in our grading methodology, and how we stay independent on our about page.